PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

INSIGHTS+

Disease of the Month: AIDS

“Putting Ourselves to the Test: Achieving Equity to End HIV” -Theme of the year 2022 Introduction: HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system. HIV, a type of retrovirus that isn't…

BySenior EditorDecember 20, 2022

EVENTS

Exclusive Coverage: CPHI & PMEC India 2022

The trade fair CPHI & PMEC India started on 29th November 2022 to unlock new business opportunities. The event was for three days (29th, 30th Nov & 1st Dec) and organized by Informa Markets at the India Expo Centre, Greater Noida, Delhi NCR with Oceanic Pharmachem Pvt Ltd as a welcome partner, and Indian Pharma Post, Express Pharma,…

BySenior EditorDecember 5, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2022

The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4B The third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

BySenior EditorSeptember 29, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…

BySenior EditorJune 30, 2022

INSIGHTS+

Top Performing Drug of 2021 – Keytruda (May Edition)

Active Ingredients: Pembrolizumab Strength: 100 mg/4 mL (25 mg/mL) Dosage Form: Syringe, Vial Mechanism of Action: PD-1 ligands antagonists First Approval: US (Sep 4, 2014), EU (Jul 17, 2015) Revenue Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…

BySenior EditorMay 26, 2022

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…

BySenior EditorMarch 31, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of December 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Samsung Bioepis presented five-year follow-up results of…

BySenior EditorJanuary 6, 2022

TOP 20

TOP 20 Animal Health Companies of 2020 by Total Revenue

Humans depends on livestock for survival and Animal Health has always been an issue to look for since it directly reflects the betterment of human life For a country’s economy and balanced human life, proper care and disease-free health of animals play a key role. Since rapid environmental change has targeted animal health, it becomes…

ByPrince GiriDecember 23, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

PharmaShots’ Key Highlights of Fourth Quarter 2022

Disease of the Month: AIDS

Exclusive Coverage: CPHI & PMEC India 2022

PharmaShots’ Key Highlights of Third Quarter 2022

PharmaShots’ Key Highlights of Second Quarter 2022

Top Performing Drug of 2021 – Keytruda (May Edition)

PharmaShots’ Key Highlights of First Quarter 2022

Insights+ Key Biosimilars Events of December 2021

TOP 20 Animal Health Companies of 2020 by Total Revenue

PharmaShots’ Key Highlights of Third Quarter 2021

Contact US

FOLLOW US